138 related articles for article (PubMed ID: 22959166)
1. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer.
He M; Tang LC; Yu KD; Cao AY; Shen ZZ; Shao ZM; Di GH
Eur J Surg Oncol; 2012 Nov; 38(11):1022-8. PubMed ID: 22959166
[TBL] [Abstract][Full Text] [Related]
2. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study.
Sohn G; Son BH; Lee SJ; Kang EY; Jung SH; Cho SH; Baek S; Lee YR; Kim HJ; Ko BS; Yu ; Lee JW; Ahn SH
J Surg Oncol; 2014 Sep; 110(3):270-4. PubMed ID: 24863883
[TBL] [Abstract][Full Text] [Related]
3. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.
Bilimoria KY; Bentrem DJ; Hansen NM; Bethke KP; Rademaker AW; Ko CY; Winchester DP; Winchester DJ
J Clin Oncol; 2009 Jun; 27(18):2946-53. PubMed ID: 19364968
[TBL] [Abstract][Full Text] [Related]
4. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
6. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
[TBL] [Abstract][Full Text] [Related]
8. Unnecessary axillary surgery for patients with node-negative breast cancer undergoing total mastectomy.
Olaya W; Morgan JW; Lum SS
Arch Surg; 2011 Sep; 146(9):1029-33. PubMed ID: 21930999
[TBL] [Abstract][Full Text] [Related]
9. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis.
Walker GV; Smith GL; Perkins GH; Oh JL; Woodward W; Yu TK; Hunt KK; Hoffman K; Strom EA; Buchholz TA
Cancer; 2010 Sep; 116(17):4000-6. PubMed ID: 20564117
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.
Hessler LK; Molitoris JK; Rosenblatt PY; Bellavance EC; Nichols EM; Tkaczuk KHR; Feigenberg SJ; Bentzen SM; Kesmodel SB
Ann Surg Oncol; 2017 Oct; 24(10):2907-2914. PubMed ID: 28766198
[TBL] [Abstract][Full Text] [Related]
11. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of occult breast carcinoma and prognostic analyses.
Wang J; Zhang YF; Wang X; Wang J; Yang X; Gao YQ; Fang Y
Chin Med J (Engl); 2013 Aug; 126(16):3026-9. PubMed ID: 23981605
[TBL] [Abstract][Full Text] [Related]
13. Implementation of sentinel node biopsy in breast cancer patients in the Netherlands.
Ho VK; van der Heiden-van der Loo M; Rutgers EJ; van Diest PJ; Hobbelink MG; Tjan-Heijnen VC; Dirx MJ; Reedijk AM; van Dijck JA; van de Poll-Franse LV; Schaapveld M; Peeters PH
Eur J Cancer; 2008 Mar; 44(5):683-91. PubMed ID: 18314328
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
[TBL] [Abstract][Full Text] [Related]
16. Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis.
Macedo FI; Eid JJ; Flynn J; Jacobs MJ; Mittal VK
Ann Surg Oncol; 2016 Jun; 23(6):1838-44. PubMed ID: 26832884
[TBL] [Abstract][Full Text] [Related]
17. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
[TBL] [Abstract][Full Text] [Related]
18. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
Goyal A; Newcombe RG; Chhabra A; Mansel RE
Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases.
Wang X; Zhao Y; Cao X
Breast J; 2010; 16(1):32-7. PubMed ID: 20465598
[TBL] [Abstract][Full Text] [Related]
20. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
